We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. CorMedix Inc. tops our list for being one of the high growth stocks.
TheFly reported on January 23 that H.C. Wainwright lowered the price target on CRMD to $13 from $18 while keeping a Buy rating. The adjustment reflects updated guidance for 2026–2027 related to DefenCath. The firm noted that CRMD has now entered a phase where clinical results will play a larger role than commercial performance in shaping the company’s future.
Similarly, on January 21, RBC Capital lowered the price target on CorMedix Inc. (NASDAQ:CRMD) to $13 from $22 while maintaining an Outperform rating. The firm updated its models for several biotech companies following discussions with management.
CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company developing and commercializing therapeutic products to prevent and treat serious diseases. Its lead product, DefenCath, is an FDA‑approved catheter lock solution that reduces bloodstream infections in hemodialysis patients.
While we acknowledge the potential of CRMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
